• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低水平和高水平V617F等位基因负荷下骨髓形态学与外周血检查结果的比较

A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level V617F Allele Burden.

作者信息

Babarović Emina, Marijić Blažen, Vranić Luka, Ban Josipa, Valković Toni, Hadžisejdić Ita

机构信息

Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.

Laboratory for Molecular Pathology, Clinical Department of Pathology and Cytology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia.

出版信息

Diagnostics (Basel). 2023 Jun 16;13(12):2086. doi: 10.3390/diagnostics13122086.

DOI:10.3390/diagnostics13122086
PMID:37370982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10296850/
Abstract

Cases with low level V617F mutations are increasingly detected; however, the clinical interpretation of the low allele burden may be challenging. The aim of this study is to analyze and compare the bone marrow morphology and peripheral blood findings in the low level V617F allele burden (≤15% of ) and high V617F mutation burden patients (>15% ). In total, 122 V617F positive cases with concomitant bone marrow biopsies and peripheral blood findings were re-evaluated (62 low and 60 high level V617F positive). Within the low burden group, normal looking megakaryocytes ( = 0.0005) were more frequently found, compared with those with no atypia ( = 0.0003), their number was more frequently not increased ( = 0.009), and they did not form clusters ( = 0.001). We found statistically significant difference in the number of platelet ( = 0.0003) and hematocrit levels ( = 0.032) when comparing the V617F <3% and ≥3% mutation burden. In the high-level burden, the megakaryocytes were more frequently atypical ( = 0.054), and more frequently formed clusters ( = 0.053) with nuclei with maturation defects ( ≤ 0.0001). In conclusion, the V617F mutation burden is reflected by morphological changes in the bone marrow and careful follow up of each and every patient with a low V617F positivity is mandatory.

摘要

低水平V617F突变的病例越来越多地被检测到;然而,低等位基因负担的临床解读可能具有挑战性。本研究的目的是分析和比较低水平V617F等位基因负担(≤15%)和高V617F突变负担患者(>15%)的骨髓形态和外周血检查结果。总共对122例伴有骨髓活检和外周血检查结果的V617F阳性病例进行了重新评估(62例低水平和60例高水平V617F阳性)。在低负担组中,与无异常的巨核细胞相比,外观正常的巨核细胞更常见(P = 0.0005),其数量更常未增加(P = 0.009),且它们不形成簇(P = 0.001)。当比较V617F <3%和≥3%突变负担时,我们发现血小板数量(P = 0.0003)和血细胞比容水平(P = 0.032)存在统计学显著差异。在高负担组中,巨核细胞更常出现异常(P = 0.054),更常形成簇(P = 0.053),且细胞核存在成熟缺陷(P≤0.0001)。总之,V617F突变负担通过骨髓形态变化得以体现,对每例V617F低阳性患者进行仔细随访是必要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/298c/10296850/730f7ff0e8a2/diagnostics-13-02086-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/298c/10296850/730f7ff0e8a2/diagnostics-13-02086-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/298c/10296850/730f7ff0e8a2/diagnostics-13-02086-g001.jpg

相似文献

1
A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level V617F Allele Burden.低水平和高水平V617F等位基因负荷下骨髓形态学与外周血检查结果的比较
Diagnostics (Basel). 2023 Jun 16;13(12):2086. doi: 10.3390/diagnostics13122086.
2
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
3
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.JAK2 V617F突变、自发性红细胞生成和巨核细胞生成、高敏血小板、活化白细胞以及内皮细胞在真性红细胞增多症和原发性血小板增多症血栓形成表现病因中的作用。
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):381-98. doi: 10.1055/s-2006-942759.
4
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.JAK2 p.V617F 检测及等位基因负荷在骨髓和外周血中的检测在骨髓增殖性肿瘤患者中的应用。
Blood. 2013 Nov 28;122(23):3784-6. doi: 10.1182/blood-2013-07-515676. Epub 2013 Sep 25.
5
Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.JAK2 V617F 等位基因负担在鉴别慢性粒单核细胞白血病与伴单核细胞增多的原发性骨髓纤维化中的作用。
Hum Pathol. 2019 Mar;85:290-298. doi: 10.1016/j.humpath.2018.10.026. Epub 2018 Nov 15.
6
Comparability of JAK2 p.V617F allele burden in peripheral blood and that in bone marrow in patients with suspected myeloproliferative neoplasms: a single-center prospective study.疑似骨髓增殖性肿瘤患者外周血与骨髓中JAK2 p.V617F等位基因负荷的可比性:一项单中心前瞻性研究
Am J Transl Res. 2023 Mar 15;15(3):2084-2089. eCollection 2023.
7
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.骨髓增殖性疾病诊断标准的概念变迁以及骨髓增殖性肿瘤的分子病因学与分类:从1950年的达梅谢克到2005年的万琴克尔及以后
Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7.
8
[Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].JAK2 V617F突变与慢性骨髓增殖性疾病关系的临床研究
Zhonghua Xue Ye Xue Za Zhi. 2008 Feb;29(2):105-9.
9
Clinical features and outcomes of V617F-positive polycythemia vera and essential thrombocythemia according to the V617F allele burden.根据V617F等位基因负荷的V617F阳性真性红细胞增多症和原发性血小板增多症的临床特征及转归
Blood Res. 2021 Dec 31;56(4):259-265. doi: 10.5045/br.2021.2021089.
10
Inhibition of Osteoblast Differentiation by JAK2 Megakaryocytes Derived From Male Mice With Primary Myelofibrosis.原发性骨髓纤维化雄性小鼠来源的JAK2巨核细胞对成骨细胞分化的抑制作用
Front Oncol. 2022 Jul 8;12:929498. doi: 10.3389/fonc.2022.929498. eCollection 2022.

引用本文的文献

1
Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2 variant allelic fraction in a real-world cohort.分子特征在真实世界队列中对JAK2变异等位基因分数低的骨髓增殖性肿瘤患者诊断中的贡献
Ann Hematol. 2025 Mar;104(3):1587-1596. doi: 10.1007/s00277-025-06326-w. Epub 2025 Apr 1.

本文引用的文献

1
JAK2 in Myeloproliferative Neoplasms: Still a Protagonist.JAK2在骨髓增殖性肿瘤中的作用:依然是主角。
Pharmaceuticals (Basel). 2022 Jan 28;15(2):160. doi: 10.3390/ph15020160.
2
Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure.不定潜能的克隆性造血:炎症、血管疾病和心力衰竭之间的交集。
Clin Sci (Lond). 2021 Apr 16;135(7):991-1007. doi: 10.1042/CS20200306.
3
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
血栓形成和血细胞计数正常患者 JAK2 V617F 突变的低发生率:一项回顾性影响研究。
J Thromb Thrombolysis. 2020 Nov;50(4):995-1003. doi: 10.1007/s11239-020-02100-z.
4
Clinical consequences of clonal hematopoiesis of indeterminate potential.克隆性造血的不确定潜能的临床后果。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):264-269. doi: 10.1182/asheducation-2018.1.264.
5
Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis.患有内脏静脉血栓形成的骨髓增殖性肿瘤患者的独特临床、实验室和分子特征。
Br J Haematol. 2018 Oct;183(2):310-313. doi: 10.1111/bjh.14958. Epub 2017 Oct 19.
6
Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH.静脉血栓栓塞症患者的隐匿性癌症筛查:国际血栓与止血学会科学与标准化委员会的指南
J Thromb Haemost. 2017 Oct;15(10):2076-2079. doi: 10.1111/jth.13791. Epub 2017 Aug 29.
7
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.克隆性造血与动脉粥样硬化性心血管疾病风险
N Engl J Med. 2017 Jul 13;377(2):111-121. doi: 10.1056/NEJMoa1701719. Epub 2017 Jun 21.
8
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.低JAK2V617F等位基因负荷在临床实践中的相关性:一项单中心研究。
Oncotarget. 2017 Jun 6;8(23):37239-37249. doi: 10.18632/oncotarget.16744.
9
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类(2016年修订版)》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
10
Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.通过液滴数字PCR对慢性髓性增殖性肿瘤中JAK2 V617F突变进行灵敏且准确的定量分析。
Ann Hematol. 2016 Apr;95(5):739-44. doi: 10.1007/s00277-016-2623-0. Epub 2016 Mar 1.